Bridgefront Capital LLC acquired a new position in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,882 shares of the healthcare conglomerate's stock, valued at approximately $1,458,000. UnitedHealth Group comprises approximately 0.5% of Bridgefront Capital LLC's portfolio, making the stock its 29th largest position.
Several other large investors have also recently bought and sold shares of the stock. Norges Bank bought a new stake in shares of UnitedHealth Group in the 4th quarter valued at approximately $6,375,744,000. Raymond James Financial Inc. bought a new stake in shares of UnitedHealth Group in the 4th quarter worth about $1,914,740,000. Amundi grew its stake in UnitedHealth Group by 97.2% during the fourth quarter. Amundi now owns 6,069,100 shares of the healthcare conglomerate's stock worth $3,183,132,000 after buying an additional 2,991,470 shares during the last quarter. Proficio Capital Partners LLC raised its stake in shares of UnitedHealth Group by 76,830.4% in the fourth quarter. Proficio Capital Partners LLC now owns 1,888,641 shares of the healthcare conglomerate's stock valued at $955,388,000 after acquiring an additional 1,886,186 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in UnitedHealth Group by 12.5% during the 4th quarter. Northern Trust Corp now owns 9,503,671 shares of the healthcare conglomerate's stock valued at $4,807,527,000 after purchasing an additional 1,058,488 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. Raymond James reaffirmed a "strong-buy" rating and issued a $540.00 price target (down from $635.00) on shares of UnitedHealth Group in a report on Monday, April 21st. KeyCorp dropped their price objective on UnitedHealth Group from $650.00 to $575.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Mizuho upped their price objective on UnitedHealth Group from $600.00 to $650.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Royal Bank of Canada decreased their price target on shares of UnitedHealth Group from $655.00 to $525.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, Robert W. Baird reduced their target price on UnitedHealth Group from $640.00 to $510.00 and set an "outperform" rating on the stock in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $596.86.
Get Our Latest Stock Analysis on UnitedHealth Group
UnitedHealth Group Stock Down 2.4 %
UNH stock traded down $9.60 during mid-day trading on Tuesday, reaching $395.21. The company had a trading volume of 7,831,081 shares, compared to its average volume of 4,648,576. UnitedHealth Group Incorporated has a 52 week low of $393.11 and a 52 week high of $630.73. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.83 and a quick ratio of 0.91. The stock has a 50 day simple moving average of $493.20 and a two-hundred day simple moving average of $526.12. The company has a market capitalization of $359.73 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 1.37 and a beta of 0.56.
UnitedHealth Group (NYSE:UNH - Get Free Report) last released its quarterly earnings data on Thursday, April 17th. The healthcare conglomerate reported $7.20 earnings per share for the quarter, missing the consensus estimate of $7.29 by ($0.09). UnitedHealth Group had a return on equity of 26.69% and a net margin of 3.60%. The firm had revenue of $109.58 billion for the quarter, compared to analyst estimates of $111.56 billion. During the same quarter in the prior year, the firm earned $6.91 earnings per share. As a group, equities analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.
UnitedHealth Group Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 18th. Shareholders of record on Monday, March 10th were issued a $2.10 dividend. The ex-dividend date was Monday, March 10th. This represents a $8.40 annualized dividend and a dividend yield of 2.13%. UnitedHealth Group's dividend payout ratio is currently 35.18%.
About UnitedHealth Group
(
Free Report)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Further Reading

Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.